Nine Months 2024 Carl Zeiss Meditec AG Earnings Call Transcript
Key Points
- DORC integration contributed EUR53 million in Q3 revenue.
- Book-to-bill ratio stabilized to slightly above 1 in Q3.
- Strict cost control measures kept OpEx trending sideways.
- Positive order entry in the US market after several weak quarters.
- Strong performance in EMEA with 16% revenue growth.
- Revenue down by 1.5% to EUR1.487 billion.
- EBIT declined by 34% year-on-year to EUR163 million.
- Net income dropped by 42% to EUR180 million.
- Weaker consumer sentiment in the refractive business.
- High interest rates and difficult financing environment in North America.
Good morning, ladies and gentlemen, and welcome to the Carl Zeiss Meditec AG analyst conference nine M 2023-24 results. At this time, all participants have been placed on listen-only mode. The floor will be open for questions following the presentation. Let me now turn the floor over to your host, Sebastian Frericks, Head of Investor.
Yeah, hi, everybody. Welcome to our analyst call. With me, as usual is our management, our President and CEO, Dr. Markus Weber, and our CFO, Justus Wehmer. They will guide you through our financials with some prepared remarks and afterwards, we look forward to take your questions.
Now I'd like to hand over to Markus.
Yes.
Thank you very much, Sebastian, and also a warm good morning and welcome from my side. Ladies and gentlemen, welcome to the Nine Months '23-'24 analyst conference of Carl Zeiss
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
